Across TCGA pan-cancer cohorts, RPL23AP26 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RPL23AP26’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL23AP26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP26 is over-expressed in tumor.

BRCA are the cancer types where RPL23AP26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	+0.051	.025	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RPL23AP26 RNA expression & survival · all RPL23AP26 data types